Fabry disease is an X linked recessive disorder of glycosphingolipid metabolism resulting from a deficiency of the lysosomal hydrolase a-galactosidase
can provide more accurate heterozygote identification through the use of restriction fragment length polymorphisms (RFLPs) detected either at the a-gal locus' or by closely linked anonymous DNA sequences.4 1 A partial'3 and full length cDNA'4 15 encoding agalactosidase have been isolated from human liver Agtl 1 expression and SV40 transformed human fibroblast pcD cDNA libraries, respectively. Northern hybridisation studies '6 have shown that a 1-4 kb agal mRNA transcript is produced in normal cells. A normal size and level of a-gal mRNA production was found in 13 of 30 unrelated Fabry hemizygotes examined. The remainder had either no detectable transcript, or decreased levels of a normal sized mRNA, or decreased/normal levels of an aberrant sized mRNA. Southern hybridisation analyses of DNA from 130 unrelated Fabry hemiizgotes have detected. seven gene rearrangements,'70 including five deletions, one duplication, and one point mutation as shown by an aberrant MspI restriction site.
Two RFLPs have been identified with the full length a-gal cDNA. Sacl and NcoI'9 20 detect polymorphismswithinand 3' to the a-galgene, respectively. The SacI RFLP was found in 8% of normal alleles and in 2% of unrelated Fabry families examined. The NcoI RFLP was found in 13% of normal alleles and in 12% of Fabry families examined. No linkage disequilibrium and no recombinants between the RFLP and disease locus were detected. RFLP analysis of Fabry families may aid in carrier detection in informative families who show no gross rearrangement of the a-gal gene.
We have previously described21 a large Nova Scotia kindred in which there are approximately 30 living affected males and over 50 possible carrier females. Molecular analysis of the a-gal alleles transmitted in this kindred would enhance the accuracy of heterozygote identification, allow for the characterisation of molecular lesions in this large group, and aid in the genetic epidemiology of the historically unrelated cases of Fabry's disease in the Canadian Maritime provinces. Although we were unable to obtain cloned a-gal sequences described previously, we report the independent isolation of a cDNA for a-gal and its use for the DNA analysis of Fabry disease in Nova Scotia.
Materials and methods
ISOLATION OF AN a-GALACTO5IDASE cDNA A human cDNA library constructed by Okayama and Berg22 from SV40 transformed human fibroblasts was kindly provided by Dr R Gravel (Research Institute, Hospital for Sick Children, Toronto, Canada M5G 1X8). The Okayama and Berg cDNA library contains approximately 14X 106 independent clones. A frozen aliquot of this cDNA library was 'scraped' with the tip of a Pasteur pipette and the scrape added to liquid medium. The medium was placed in a shaker incubator overnight at 37°C. Aliquots were removed at hourly intervals for six hours and from the overnight culture. These aliquots were plated, a timegrowth curve constructed, and the number of cells present in the original 'scrape' determined. When plating the cDNA library, an appropriate number of 'scrapes' were taken to ensure that at least 106 cells were present at time 0 hours. This was done in order to optimise conditions for finding the a-gal cDNA from the 14x 106 independent clones available. The library was plated at a cell density of i04 colonies/100 m2 plate from an overnight liquid culture of the library 'scrapes'. Sterile nitrocellulose filters were overlaid on each 100 mm2 plate and the plates incubated at 37°C overnight. The nitrocellulose filters were then transferred, colony side up, to plates containing spectinomycin (100 /ml) for plasmid amplification and further incubated at 37°C overnight. The master plates were sealed with parafilm and stored at 4°C. The amplification plates were discarded. The colony lifts were denatured in 0-5 mol/l NaOH/1-5 mol/l NaCl, vacuum dried at 80°C for two hours, and stored at room temperature.
A 30mer oligodeoxynucleotide (5' AGGACTGG-CAGAAGCATTGTGTACTCCTGT 3') was commercially synthesised (Regional DNA Synthesis Laboratory, Department of Medical Biochemistry, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1) using the nucleotide sequence from a partial cDNA clone for a-gal isolated by Calhoun et al. ' 3 The 30mer oligonucleotide was 5' end labelled by T4 polynucleotide kinase using [a-32P]ATP (New England Nuclear, 3000 Ci/mmol) to a specific activity of 4 to 5 x 108cpm/lg. The colony lifts (20 filters/100 ml buffer) were prehybridised at 61°C (the calculated TM of the 30mer oligonucleotide) for four hours in 6xSSC (0-9 mol/l NaCl, 0 09 mol/l Na citrate pH 7-0)/I10x Denhardt's (0-2% Ficoll, 0-2% polyvinylpyrrolidone, 0-2% bovine serum albumin, fraction V)/50mmol/I phosphate buffered saline, pH 7 0. The radiolabelled probe was hybridised (106 cpm/ml buffer) overnight in fresh buffer at 61°C, washed in two changes of 6x SSC at 61°C, and exposed on Kodak XAR-5 film with an intensifier screen at -70°C for one to three days.
Colonies which gave a positive signal were 'picked' with the wide bore of a Pasteur pipette, amplified as overnight cultures, and replated at a cell density of 103/100 mm2 and subsequqntly 102/100 mm2 plate.
Single colony isolates which gave a positive signal after these three rounds of purification were amplified and the plasmid DNA isolated according to standard procedures.23 The plasmid DNA was restricted with BamHI to release the insert DNA and electrophoresed in a 0-8% agarose gel. The radiolabelled 30mer was hybridised in situ to the gel to confirm the identity of the a-galactosidase cDNA insert. High molecular weight DNA was prepared from human leucocytes. Peripheral venous blood was collected in EDTA treated vacutainer tubes. The red blood cells were pelleted by centrifugation and the white cell 'buffy coat' removed to a fresh tube. An isotonic solution of 00404% NH4Cl/10 mmol/l Tris, pH 7-6 (9:1) was added to the white cell suspension and the cells were incubated at 37°C for 15 minutes. The cell suspension was centrifuged, the haemolysed supernatant removed, and the white cell pellet resuspended in proteinase K buffer (10 mmol/l Tris, pH 8-0/100 mmol/l NaCI/l mmol/l EDTA, pH 7 6) containing 0-5% sodium dodecyl sulphate (SDS) and 0-5 mg/ml proteinase K and incubated at 3700 ovemight. The cell lysate was extracted with an equal High molecular weight DNA (10 Rg) was digested with the appropriate restriction enzymes and electrophoresed overnight in a 0-8% agarose gel at 0-8 volts/cm. The gel was denatured in 0 5 mmol/l NaOH/1-5 mol/l NaCl and neutralised in 0-5 molIl Tris, pH 7-5/3-0 mmol/l NaCl. The DNA was transferred onto a nitrocellulose membrane in 6x SSC for 48 hours. The membrane was rinsed briefly in 2XSSC, allowed to air dry, and baked at 80°C or two hours under vacuum.
Filters were prehybridised overnight at 65°C in 5 x SSC/5 x Denhardt's/0-1% SDS containing 250 [tg/ml of denatured salmon sperm DNA. The filter was hybridised overnight at 65°C in 10% dextran sulphate/ 5xSSC/lxDenhardt'sx0-1% SDS containing 250
[tg/ml of denatured salmon sperm DNA and 10 ng/ml of radiolabelled probe. Hybridisation probes were prepared from isolated a-gal inserts (BamHIlPstI restriction fragments of 1-3 kb) by nick translation using [a-32P]ATP (New England Nuclear, 3000
Ci/mmol) to a specific activity of 1 to 2 x 108 cpM/[lg.
The filters were washed at 65°C for two hours in three changes of 2 x SSC/0-1% SDS followed by two changes of 0-1xSSC/0 1% SDS. The filters were then air dried and exposed to Kodak XAR-5 film at -70°C with an intensifier screen for one to three days.
BLOOD SAMPLES AND a-GAL DETERMINATIONS
All blood samples were obtained after informed consent. Leucocyte isolation and measurement of leucocyte a-and ,-galactosidase activity were carried out as described previously.8 21 The a-galactosidase cDNA probe was first tested as a tool for carrier detection using leucocyte DNA from members of six families from the large Nova Scotia kindred (fig 1) . At the same time, leucocyte DNA from two other families was examined (fig 2) B1B2  BIBI  B2B2  B1B2  BIB2  BI  B1B2  B2  BIBI  B2  B1B2  B1B2  B1B2  BIBI  B2  B1B2  NT  B1B2  NT  B1B2  B1B2  B1B2  B2  B2  NT  B2  B1B2  B1B2  B1B2  NT  B2  BIBI  B1B2  B1B2  B1B2  B2  NT  B1B2  NT  BIBI  NT  BIBI  B2  B1B2  B1B2  BI  B1B2  NT  B1B2  BI  NT  B2  NT  B2  BIBI  B1B2  B2  B2  B1B2 The mutation present in these two families is not detectable by Southern analysis and therefore does not represent a major rearrangement of the a-gal gene.
The inheritance of the BI and B2 alleles in one informative family from the Nova Scotia kindred is In addition, affected males from two Nova Scotia families (fig 2) which cannot be linked to the main kindred by history were also found to carry the B2 allele (table). This suggests that these two additional families are affected by the same mutant allele transmitted in the main kindred.
A direct estimate of the recombination rate was obtained from family groups 1 to 6 (fig 1) tide sequences which are located upstream in 'housekeeping' genes) was found at bp -660 in the a-gal gene. Using pAJK-3 as a hybridisation probe, we have confirmed the presence of a polymorphic NcoI restriction site near the 3' end of the a-gal gene '9 20 located in the region Xq2l.33.5 Homozygosity for the BR (IV.1, IV.20, IV.24, IV.36, V.16, and V.22) and B2 (IV.12 and V.14) alleles establishes these two NcoI fragments as alleles with frequencies of 0-80 and 0-20, respectively, and a PIC value of 0-27.
The B2 NcoI allele was found to segregate with the Fabry disease locus in the large Nova Scotia kindred reported by Spence et Using an a-gal/03-gal ratio of 0-20 as the cut off between carrier females and controls,8 five of 21 obligate carriers had ratios in the control range and a further two fell on the dividing line. Thus 7/21 or 1/3 (33 3%) of the obligate heterozygotes in this group would have been misclassified or uncertain on the basis of enzyme analysis alone. This figure is substantially larger than the 15% we reported previously.2' The difference is not because of a change in the method or accuracy of measuring enzyme activity as similar methods were used. Some of the subjects reported here had also been studied earlier2l and their enzyme values have remained essentially unchanged. The higher figure probably reflects a selection bias during this study, since the subjects from whom blood was obtained were the most readily accessible and there was a greater proportion of persons with a high a-gal/,B-gal ratio among them. At this time, we feel that the 15% figure is still a reasonable one. The higher concordance between the clinical evidence of heterozygosity and the DNA data as compared to the enzyme data clearly illustrates the utility of the RFLP approach. It is interesting that the mean age of the obligate heterozygotes who tested indistinguishably from the controls in the enzyme assays was 40 years, whereas in the rest of the group it was 24 years. This age related difference may be important, since age related changes in the stability of X chromosome inactivation have been reported. 7 Accurate heterozygote detection and prenatal diagnosis are now possible in this kindred using the NcoI RFLP. Recombination between the mutation and the NcoI polymorphism appears to be negligible and linkage of the mutation to the rarer allele suggests that the majority of carrier females should be heterozygous for the polymorphism (17/17 obligate carriers analysed molecularly were B1B2) and thus allow predictive diagnosis by linkage analysis. This RFLP has even more general utility as it has also been identified by us in several isolated cases of Fabry disease in Nova Scotia with no known relationship to our kindred.
Based on the association between the B2 NcoI allele and the Fabry disease locus, carrier status was excluded for subject V. 16 . This patient had borderline levels of enzyme activity (0-19 as compared to a control value of 0-20, table) but was shown to be homozygous for the Bl allele, thereby eliminating her risk of being a carrier. Subject V. 1 also had borderline levels of enzyme activity and was heterozygous for the BI and B2 alleles. However, carrier status could not be established in this patient, as her mother (IV. 14) was homozygous for the B2 allele and the origin of the patient's B2 allele could not be determined. Determination of carrier status in V.1 may be aided by establishing a haplotype of the affected X chromosome from one of her affected uncles (IV.4, 6, 9, 12). Haplotype analysis would also be helpful in delineating the carrier status of IV. 17, whose father is dead.
Patient IV. 1, the daughter of obligate carrier III.2 (Bl/B2), is homozygous for the Bl allele and therefore not a Fabry carrier. Patient IV. 14, also the daughter of obligate carrier III.2 (Bl/B2), is a Fabry carrier by enzyme assay (table) and is homozygous for the B2 allele.
Restriction analysis of our Fabry patients' DNA showed no gross deletions or rearrangements. A previous study of 130 unrelated families with Fabry disease has shown that only seven (5-39%) have detectable molecular rearrangements by Southern analysis.'8 Five partial gene deletions, ranging in size from 0 4 to 5-5 kb, were identified. Four of these deletions had a breakpoint in intron 2, suggesting that the Alu sequences found in this intron may lead to unequal crossover events. The fifth deletion had a breakpoint in exon 5. A gene duplication of exons 2 to 6 was also identified. A point mutation resulting in the loss of an MspI restriction site in exon 7 was found in a Fabry hemizygote who had approximately 2% residual a-gal activity. The altered MspI site was a missense mutation resulting from a G-CT transition at position 1066 in the cDNA with a consequent arginine to tryptophan substitution at residue 356. No a-gal mRNA was detected in any of the six Fabry hemizygotes carrying these gene rearrangements. RNase A protection studies showed a deletion of the 198 bp exon 6 in the seventh Fabry family with a normal gene profile on Southern analysis but a shortened mRNA transcript. These reports indicate that Fabry disease is caused by a heterogeneous set of mutations in the a-gal gene, but that the majority of mutations are as yet unidentified. Lemansky Further mRNA studies are currently under way to identify the molecular lesion of the a-galactosidase present in our Nova Scotia kindred. This will allow for more precise carrier analysis in at risk females who are not inforiative for the NcoI allele.
